MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Cytokines in CSF and plasma as potential biomarkers for PD cognitive impairment

M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergaretxe-Yarza, J.F. Martí-Massó, P. Martínez-Lage, A. Izagirre, A. Oregi, L. Sepúlveda, M.C. Rodríguez-Oroz (San Sebastián, Spain)

Meeting: 2016 International Congress

Abstract Number: 1388

Keywords: Cognitive dysfunction

Session Information

Date: Wednesday, June 22, 2016

Session Title: Parkinson's disease: Cognition

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To assess CSF and plasmatic levels of cytokines as potential biomarkers of PD and PD mild cognitive impairment (PD-MCI).

Background: Neuroinflammation may play a role in the pathogenesis of PD. Cytokine levels are increased and microglia is activated in several cerebral areas of PD patients. In addition, cognitive impairment has been associated with inflammation, as IL-6, IL-1, and IL-1ß CSF levels are increased in PD-MCI patients.

Methods: 40 PD patients and 40 controls underwent clinical and neuropsychological evaluation (at least two test for each cognitive domain) and lumbar puncture. According to their cognitive state patients were classified as cognitively normal (PDCN) (n=15) or with PD-MCI (n=22). CSF levels of IL-1ß, IL-2, IL-6, IFNγ, and TNF-α were measured using multiplex technology. Cytokines with detectable levels in CSF (IL-6 and TNF-α) were individually assessed in plasma using commercial ELISA kits (R&D Systems, Minneapolis, MN, USA).

Results: Concentration of IL-1ß, IL-2, and IFNγ in CSF were below the detection threshold in all the subjects. Levels of IL-6 did not differ between patients and controls (0.617 ± 0.30 vs. 0.531 ± 0.22 pg/mL; p=0.346). Adjusting for age, TNF-α levels were higher in patients than in controls (0.4013 ± 0.158 vs. 0.3078 ± 0.124 pg/mL; p=0.021. In plasma, IL-6 levels were not different between groups (2.294 ± 2.66 vs. 1.917 ± 1.27 pg/mL; p=0.742) and TNF-α levels were under the detection threshold. There was no difference in CSF IL-6 and TNF-α levels and plasmatic IL-6 levels between PDCN and PD-MCI patients. In contrast, IL-6 plasmatic levels negatively correlated with the composite z score of attention and working memory (r=-0.378; p=0.009), executive function (r=-0.359; p=0.016), language (r=-0.553; p<0.001), global cognition z score (r=-0.411; p=0.005), MMSE (r=-0.383; p=0.01), and MOCA (r=-0.429; p=0.003). After adjusting for age, only correlation with language remained significant (corrected p=0.009).

Conclusions: In PD patients, CSF levels of TNF-α are elevated and plasmatic levels of IL-6 negatively correlated with cognitive outcome in language. As decline in semantic fluency has been associated with progression to dementia, plasma IL-6 could deserve further studies as potential biomarker of cognitive dysfunction in PD.

To cite this abstract in AMA style:

M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergaretxe-Yarza, J.F. Martí-Massó, P. Martínez-Lage, A. Izagirre, A. Oregi, L. Sepúlveda, M.C. Rodríguez-Oroz. Cytokines in CSF and plasma as potential biomarkers for PD cognitive impairment [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/cytokines-in-csf-and-plasma-as-potential-biomarkers-for-pd-cognitive-impairment/. Accessed May 17, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/cytokines-in-csf-and-plasma-as-potential-biomarkers-for-pd-cognitive-impairment/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley